Clinical Data Novo says high-dose Wegovy can cause 28% weight loss PharmaphorumNovo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.Metabolic & GLP-1Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Pharmaphorum Novo Nordisk has built the case for migration to its ‘triple-dose’ version of injectable GLP-1 Wegovy with new weight-loss and body composition data. Metabolic & GLP-1 Read full story Post navigation Previous: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)Next: BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026 Clinical Data Viridian data lift prospects for thyroid eye disease drug pharminent May 5, 2026
